Abbott said its test results show Absorb, its new dissolving stent, works just as well and is just as secure as Xience, Abbott's best stent that gradually lets out a medication to stop cells from quickly replicating, in the time between one and two years following when the stents were implanted.
The outcomes of the Absorb test did not reveal any contrasts in the numbers between the two in target lesion failure and stent thrombosis in the time between one and two years following the placement of the stents, Abbott said in a release. Of those who had the Absorb stent, 3.7 percent experienced target lesion failure, while 2.5 percent of those who had the Xience stent experienced target lesion failure. Of those who had the Absorb stent, 0.3 percent went through stent thrombosis, while none of those who had the Xience stent had stent thrombosis.
After two years, a bigger percentage of those who used the Absorb stent experienced target lesion failure than the percentage of those who used the Xience stent, especially when the stent went into small vessels, as 19 percent of all who were in the test had target lesion failure. Of that 19 percent, 11 percent used the Absorb stent, and 7.9 percent used the Xience stent.
"When implanted in appropriate vessel sizes and following current instructions for use, the results for Absorb are comparable to Xience, the gold standard drug-eluting stent, with the added feature of leaving no metal behind once it dissolves," Charles Simonton, chief medical officer and divisional vice president of medical affairs for Abbott's vascular business, said in the release.